secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001654954-24-003500
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics reports FY 2023 net loss; cash runway into Q3 2024; Phase 3 acne trial underway
--------------------------------------------------------------------------------

- Cash and equivalents $7.4M as of Dec 31, 2023 vs $6.2M in 2022; expects to fund ops into Q3 2024.
- Net proceeds of $7.6M from three 2023 financings partially offset $6.4M cash used in operations.
- R&D expenses $4.1M in 2023 (down from $5.7M in 2022) due to lower clinical costs offset by CMC for Phase 3.
- Enrollment initiated in DMT310 Phase 3 STAR-1 acne trial in Q4 2023; topline results expected Q1 2025.
- Japanese patent issued for DMT410 for hyperhidrosis; partnership discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/0001654954-24-003500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-003500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer